dc.contributor.author | PEHLİVAN, Sacide | |
dc.contributor.author | Serin, Istemi | |
dc.contributor.author | Oyaci, Yasemin | |
dc.contributor.author | Pehlivan, Mustafa | |
dc.date.accessioned | 2022-07-04T13:16:21Z | |
dc.date.available | 2022-07-04T13:16:21Z | |
dc.identifier.citation | Serin I., Oyaci Y., Pehlivan M., PEHLİVAN S., "Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms", Cytokine, cilt.153, 2022 | |
dc.identifier.issn | 1043-4666 | |
dc.identifier.other | av_4176c6c7-db4a-4af4-a424-9986cec78adb | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/182479 | |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85125770616&origin=inward | |
dc.identifier.uri | https://doi.org/10.1016/j.cyto.2022.155851 | |
dc.description.abstract | © 2022 Elsevier LtdIntroduction: The IL-1 receptor antagonist (IL-1Ra or IL-1RN) is a member of the IL-1 superfamily that functions as a competitive antagonist of the cell surface IL-1 receptor, thereby regulating various immune and inflammatory responses related to IL-1. IL-1 induces tumor growth and metastasis, while IL-1RN inhibits the secretion of IL-1α and IL-6 in cancer cells. Interleukin-4 (IL-4) is a potent anti-inflammatory cytokine, can be secreted by many types of immune cells. In this study, it was aimed to reveal the effects of IL-1RN and IL-4 VNTR polymorphisms on disease development and survival in patients with multiple myeloma (MM). Material and methods: In this study, 244 patients diagnosed with MM in hematology clinic between January 2010 and January 2021, and 179 healthy individuals were included. The genotypes of the IL-1RN VNTR polymorphism were statistically compared before treatment between patients having undergone stem cell transplantation and healthy controls, as were the genotypes of IL-4 VNTR polymorphism. Additionally, the statistically significant effects of these genotypes on survival were examined. Results: In the statistical analysis of the distribution of IL-1RN VNTR gene variants, 1/3 and 1/4 genotypes were found to be significantly higher in patients with MM compared to the healthy controls (p = 0.035). There was no significant difference between the MM patient group and the healthy controls in terms of IL-4 VNTR genotype distribution. PFS of patients with IL-1RN VNTR non-2-allele carrier genotypes was significantly shorter, but no significant effect was found on OS (p = 0.03, p = 0.786, respectively). Patients with IL-1RN VNTR non-2-allele carrier genotypes had 1.718-fold increased risk of shorter PFS. Conclusions: In conclusion, with this study, the effects of IL-1RN VNTR and IL-4 VNTR polymorphisms on MM were evaluated for the first time in the literature. This study will shed light on ones on cytokine-MM relationship and epigenetic mechanisms. | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | BİYOKİMYA VE MOLEKÜLER BİYOLOJİ | |
dc.subject | HEMATOLOJİ | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Immunology and Allergy | |
dc.subject | Health Sciences | |
dc.subject | Immunology | |
dc.subject | Life Sciences | |
dc.subject | Biochemistry | |
dc.subject | Molecular Biology | |
dc.subject | Hematology | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Sitogenetik | |
dc.subject | Temel Bilimler | |
dc.subject | Hematoloji | |
dc.subject | ALERJİ | |
dc.subject | Moleküler Biyoloji ve Genetik | |
dc.subject | İmmünoloji | |
dc.subject | Klinik Tıp | |
dc.subject | Moleküler Biyoloji ve Genetik | |
dc.title | Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms | |
dc.type | Makale | |
dc.relation.journal | Cytokine | |
dc.contributor.department | University of Health Sciences , , | |
dc.identifier.volume | 153 | |
dc.contributor.firstauthorID | 3405972 | |